Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases
- Cetuximab/panitumumab. // Reactions Weekly;5/9/2009, Issue 1251, p12
The article describes several case reports involving three men, aged 64 to 68 years, who developed hypomagnesaemia during treatment with panitumumab for metastatic colorectal cancer. During cetuximab treatment and later during panitumumab treatment, patient one developed hypomagnesaemia. Patient...
- P-0210A PHASE II STUDY OF BEVACIZUMAB COMBINED WITH MODIFIED OPTIMOX-1 AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER. Sasaki, Eisaku; Sato, Atsushi; Nakayama, Norisuke; Tanaka, Soichi; Shimada, Ken; Konishi, Kazuo; Hibi, Kenji; Yamada, Toshio; Kikuchi, Yoshinori; Hayashi, Kazuhiko; Nishina, Haruhiro; Sasaki, Tsuneo; Kurihara, Minoru // Annals of Oncology;Jun2013, Vol. 24 Issue suppl_4, piv95
No abstract available.
- Panitumumab. // Reactions Weekly;1/9/2010 Part 2 of 2, Issue 1283, p72
The article describes the case of two patients who experienced infusion reactions while undergoing treatment with panitumumab for metastatic colorectal cancer.
- Capecitabine. // Reactions Weekly;1/14/2012, Issue 1384, p16
The article describes a case of erythrodysaesthesia in a 68-year-old man while receiving capecitabine for metastatic colon carcinoma.
- Gefitinib. // Reactions Weekly;7/16/2011, Issue 1360, p18
The article describes the case of a man with recurrent colon cancer who was given cetuximab, bavacizumab and gefitinib who developed skin rash.
- Antineoplastics. // Reactions Weekly;12/17/2011, Issue 1382, p8
The article describes the case of a 57-year-old woman with metastatic colon cancer who developed tracheal necrosis associated with mediastinal extravasation from a Port-a-cath (PAC) device during palliative chemotherapy with folinic acid, irinotecan, fluorouracil (FOLFIRI) and bevacizumab.
- Estrogen receptor modulators. // Reactions Weekly;5/15/2010, Issue 1301, p22
The article describes the case of two women who developed colorectal cancer while undergoing treatment with estrogen receptor modulators, namely anastrozole, exemestane and letrozole.
- Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Shimura, T.; Fuse, N.; Yoshino, T.; Minashi, K.; Tahara, M.; Doi, T.; Joh, T.; Ohtsu, A. // Annals of Oncology;Oct2010, Vol. 21 Issue 10, p2005
Background: Chemotherapy-induced interstitial lung disease (ILD) in colorectal cancer (CRC) patients is rarely reported, but its clinical features remain to be clarified.Patients and methods: Using a computerized database, we retrospectively identified patients who developed ILD from 734...
- Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Schultheis, B.; Folprecht, G.; Kuhlmann, J.; Ehrenberg, R.; Hacker, U. T.; Köhne, C. H.; Kornacker, M.; Boix, O.; Lettieri, J.; Krauss, J.; Fischer, R.; Hamann, S.; Strumberg, D.; Mross, K. B. // Annals of Oncology;Jun2013, Vol. 24 Issue 6, p1560
Background Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan. The multitargeted kinase inhibitor, regorafenib, was combined with chemotherapy as first- or second-line treatment of mCRC to assess safety and pharmacokinetics...